Skip to content
Back to ADMA

Adma Biologics, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
19
Purchases
5
Sales
14
Purchase value
$468.29K
Sale value
$3.76M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Lawrence P. GuiheenDirector
4
Filed Nov 16, 2026Period of report Nov 16, 20260001140361-26-044293
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 16, 2026
Common StockF1F210,000$13.92$139.20K63,599Direct
Filing footnotes · 6
  1. F1The price reported in Column 4 is the price at which the shares were sold.
  2. F2Includes, as of the transaction date, (i) 5,345 unvested restricted stock units ("RSUs") granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date and that will be settled into common stock upon vesting; and (ii) 58,254 shares of common stock owned by the Reporting Person. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
  3. F3These shares are held in the Lawrence P Guiheen Revocable Trust DTD 9/20/19, over which the Reporting Person retains control.
  4. F4These shares are held in the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE ("Guiheen Irrevocable Trust"), over which the Reporting Person retains control. The Reporting Person disclaims beneficial ownership of the securities held by the Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
  5. F5The option was granted on February 14, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on February 14, 2019.
  6. F6The option terminates on the earlier of (i) February 14, 2027 and (ii) the one-year anniversary of the Reporting Person's ceasing to serve as a director of the Issuer. The Reporting Person is exercising this option due, in part, to its near-term expiration date.
Open on SEC EDGAR
Adam S GrossmanDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Nov 16, 2026Period of report Nov 16, 20260001140361-26-044291
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 16, 2026
Common StockF1F215,000$13.72$205.80K2,070,777Direct
SaleNov 16, 2026
Common StockF1F2F3F4F56,000$13.72$82.32K2,064,777Direct
Filing footnotes · 8
  1. F1Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
  2. F2The price reported in Column 4 is the price at which the shares were sold.
  3. F3Includes, as of the transaction date, (i) 282,529 unvested restricted stock units ("RSUs") granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  4. F4(continued from footnote 3) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023, vesting quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  5. F5(continued from footnote 4) and (v) 1,170,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
  6. F6These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
  7. F7These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
  8. F8The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Open on SEC EDGAR
Adam S GrossmanDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Nov 5, 2026Period of report Nov 5, 20260001140361-26-042166
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 5, 2026
Common StockF1F2105,000$12.00$1.26M2,112,777Direct
SaleNov 5, 2026
Common StockF1F2F3F4F542,000$12.00$504.00K2,070,777Direct
Filing footnotes · 8
  1. F1Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
  2. F2The price reported in Column 4 is the price at which the shares were sold.
  3. F3Includes, as of the transaction date, (i) 282,529 unvested restricted stock units ("RSUs") granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  4. F4(continued from footnote 3) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023, vesting quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  5. F5(continued from footnote 4) and (v) 1,176,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
  6. F6These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
  7. F7These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
  8. F8The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Open on SEC EDGAR
Jerrold B GrossmanDirector
4
Filed May 28, 2026Period of report May 27, 20260001140361-26-023127
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 27, 2026
Common StockF1F26,400$7.91$50.62K520,284Direct
Filing footnotes · 6
  1. F1Represents an open market purchase in a single transaction.
  2. F2Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 509,594 shares of common stock owned by the Reporting Person.
  3. F3These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood.
  4. F4These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
  5. F5These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis.
  6. F6These shares are owned by the Reporting Person's wife.
Open on SEC EDGAR
Jerrold B GrossmanDirector
4
Filed May 14, 2026Period of report May 12, 20260001140361-26-021150
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 12, 2026
Common StockF1F212,500$8.01$100.13K513,884Direct
Filing footnotes · 6
  1. F1Represents an open market purchase in a single transaction.
  2. F2Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 503,194 shares of common stock owned by the Reporting Person.
  3. F3These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood.
  4. F4These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
  5. F5These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis.
  6. F6These shares are owned by the Reporting Person's wife.
Open on SEC EDGAR
Jerrold B GrossmanDirector
4
Filed May 12, 2026Period of report May 11, 20260001140361-26-020855
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 11, 2026
Common StockF1F212,500$8.01$100.13K501,384Direct
Filing footnotes · 6
  1. F1Represents an open market purchase in a single transaction.
  2. F2Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 490,694 shares of common stock owned by the reporting person.
  3. F3These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood.
  4. F4These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
  5. F5These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis.
  6. F6These shares are owned by the Reporting Person's wife.
Open on SEC EDGAR
Adam S GrossmanDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Mar 17, 2026Period of report Mar 16, 20260001140361-26-009899
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 16, 2026
Common StockF1F215,000$15.16$227.40K2,118,777Direct
SaleMar 16, 2026
Common StockF1F2F3F4F56,000$15.16$90.96K2,112,777Direct
Filing footnotes · 8
  1. F1Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
  2. F2The price reported in Column 4 is the price at which the shares were sold.
  3. F3Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  4. F4(continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  5. F5(continued from footnote 3) and (v) 1,218,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
  6. F6These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
  7. F7These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
  8. F8The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Open on SEC EDGAR
Kaitlin M. Kestenberg-MessinaCOO and SVP, Compliance
4
Filed Mar 10, 2026Period of report Mar 6, 20260001140361-26-008905
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 9, 2026
Common StockF3F4F5F610,096$15.63$157.80K466,600Direct
Filing footnotes · 11
  1. F1Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.
  2. F10The incentive stock options were granted to the Reporting Person on February 25, 2021, and are fully vested.
  3. F11The incentive stock options were granted to the Reporting Person on July 19, 2021, and are fully vested.
  4. F2The shares were transferred by the reporting person in accordance with the terms of a court-approved divorce settlement agreement (the "Divorce Settlement").
  5. F3The securities were sold by the Reporting Person in accordance with the terms of the Divorce Settlement.
  6. F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.59 to $15.65, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  7. F5Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 58,338 unvested RSUs out of 77,784 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;
  8. F6(continued from footnote 5) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 23,750 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; and (vi) 133,641 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
  9. F7The incentive stock options were granted to the Reporting Person on February 14, 2017, and are fully vested.
  10. F8The incentive stock options were granted to the Reporting Person on June 5, 2019, and are fully vested.
  11. F9The incentive stock options were granted to the Reporting Person on August 19, 2020, and are fully vested.
Open on SEC EDGAR
Steve ElmsDirector
4
Filed Mar 9, 2026Period of report Mar 5, 20260001140361-26-008363
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 6, 2026
Common StockF2F4F37,000$15.39$107.73K2,045,730IndirectSee footnote
PurchaseMar 5, 2026
Common StockF1F2F37,000$15.67$109.69K2,038,730IndirectSee footnote
Filing footnotes · 5
  1. F1The reported transaction reflects the open market purchase of shares of ADMA Biologics, Inc. (the "Issuer") common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.58 to $15.74, inclusive.
  2. F2The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4.
  3. F3Includes (i) 2,031,730 shares owned by Aisling Capital II LP, which is a fund that was established in 2007 with a 10 year life ("Aisling Capital"), and (ii) 14,000 shares owned by Aisling Arcturus Partners, LP ("Aisling Arcturus" and, together with Aisling Capital, "Aisling"), of which 7,000 were purchased on March 5, 2026 and 7,000 were purchased on March 6, 2026. Mr. Elms is Aisling Capital's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of the Issuer's shares owned by Aisling and Aisling Partners' ownership of the Issuer's options, except to the extent of his pecuniary interest therein.
  4. F4The reported transaction reflects the open market purchase of shares of the Issuer's common stock. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.35 to $15.42, inclusive.
  5. F5Includes, as of the transaction date, (i) 10,690 restricted stock units granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 87,330 shares of common stock owned by the Reporting Person.
Open on SEC EDGAR
Adam S GrossmanDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Feb 17, 2026Period of report Feb 17, 20260001140361-26-005888
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 17, 2026
Common StockF1F215,000$16.08$241.20K2,290,379Direct
SaleFeb 17, 2026
Common StockF1F2F3F4F56,000$16.08$96.48K2,284,379Direct
Filing footnotes · 8
  1. F1Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.
  2. F2The price reported in Column 4 is the price at which the shares were sold.
  3. F3Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  4. F4(continued from footnote 3) (iii) 418,296 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 286,848 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  5. F5(continued from footnote 4) (v) 75,000 unvested RSUs out of 300,000 RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (vi) 969,684 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
  6. F6These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.
  7. F7These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.
  8. F8The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Open on SEC EDGAR
Adam S GrossmanDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Dec 16, 2025Period of report Dec 15, 20250001140361-25-045737
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 15, 2025
Common StockF1F215,000$19.79$296.85K2,013,850Direct
SaleDec 15, 2025
Common StockF1F2F3F4F56,000$19.79$118.74K2,007,850Direct
Filing footnotes · 8
  1. F1Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.
  2. F2The price reported in Column 4 is the price at which the shares were sold.
  3. F3Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  4. F4(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  5. F5(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 975,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
  6. F6These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
  7. F7These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.
  8. F8The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Open on SEC EDGAR
Adam S GrossmanDirector · President and CEO
4Rule 10b5-1 plan disclosed
Filed Nov 21, 2025Period of report Nov 19, 20250001140361-25-042997
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 19, 2025
Common StockF1F215,000$16.00$240.00K2,019,850Direct
SaleNov 19, 2025
Common StockF1F2F3F4F56,000$16.00$96.00K2,013,850Direct
Filing footnotes · 8
  1. F1Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the reporting person and Fidelity Brokerage Services LLC on December 5, 2024, as previously disclosed by the issuer.
  2. F2The price reported in Column 4 is the price at which the shares were sold.
  3. F3Includes, as of the transaction date, (i) 252,022 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 418,296 unvested RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  4. F4(continued from footnote 3) (iii) 286,848 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
  5. F5(continued from footnote 4) (iv) 75,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (v) 981,684 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
  6. F6These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
  7. F7These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.
  8. F8The option was granted on February 26, 2024 and vests over four years with 25% of the shares of common stock underlying the option (i.e., 217,737 shares) vesting on February 26, 2025, the one-year anniversary of the date of grant, and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 26, 2028.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.